ESMO: Merck Sees Keytruda-Lenvima Potential In Melanoma, Hard-To-Treat Cancers
Also Promising In Ovarian And Colorectal
Keytruda-Lenvima picked out as pick of combination therapies from the European cancer congress.
You may also be interested in...
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.